Tyra Biosciences (TYRA) announced that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib is a potential first-in-class, once-daily oral FGFR3 selective inhibitor that was discovered using the TYRA’s in-house SNAP platform.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Bioscience: Strategic Advancements and Financial Stability Justify Buy Rating
- Tyra Bioscience: Promising Clinical Trials and Financial Stability Justify Buy Rating
- Tyra Biosciences Advances Clinical Programs with Strong Financial Backing
- Tyra Biosciences reports Q2 EPS (47c), consensus (51c)
- Tyra Biosciences announces presentation on TYRA-300 preclinical results at ENDO